Complexo Hospitalario Universitario De Pontevedra

The dermatology department is running studies that evaluate new antimicrobial strategies for serious infections such as tuberculosis and nontuberculous mycobacterial lung infection, aiming to improve cure rates and reduce treatment duration.

• High‑dose rifampicin, moxifloxacin and linezolid regimen for pulmonary tuberculosis
• Amikacin liposome inhalation combined with standard therapy for nontuberculous mycobacterial disease
• Safety assessment of investigational anti‑mycobacterial compounds

The site supports 45 clinical trials with 31 investigators, highlighting its active role in infectious disease research.

Research focuses on preventing clotting complications in high‑risk patients and testing novel agents that lower lipoprotein(a) to reduce cardiovascular events.

• Low‑molecular‑weight heparin prophylaxis in metastatic colorectal cancer
• Muvalaplin evaluation for major adverse cardiovascular events
• Lipid‑lowering therapy targeting elevated lipoprotein(a) levels

Studies are conducted under the hospital’s multidisciplinary framework, integrating cardiology expertise.

Trials address a spectrum of liver disorders, from fatty liver disease to cholestatic conditions, testing agents that may reverse fibrosis or improve liver function in NASH and related diseases.

• Semaglutide for NASH with advanced fibrosis
• Elafibranor in primary biliary cholangitis with inadequate response
• Pegozafermin in compensated cirrhosis due to metabolic dysfunction‑associated steatotic liver disease

The department collaborates with hepatology specialists to ensure comprehensive patient monitoring.

Oncology investigations target plasma cell malignancies, especially multiple myeloma, seeking more effective induction regimens and maintenance approaches.

• KRd versus standard VMP‑Rd in newly diagnosed multiple myeloma
• Teclistamab compared with PVd/Kd in relapsed or refractory myeloma
• Isatuximab‑VRD with early rescue intervention for transplant‑eligible patients

Hematology collaborators provide expertise in disease assessment and response monitoring.

Studies evaluate biologic therapies for immune‑mediated skin conditions, aiming to control symptoms and improve quality of life in disorders such as chronic spontaneous urticaria and atopic dermatitis.

• Barzolvolimab for chronic spontaneous urticaria
• Long‑term safety of amlitelimab in moderate to severe atopic dermatitis
• Dupilumab for chronic pruritus of unknown origin

Immunology experts guide patient selection and immunophenotypic analyses.

Oncology programs include preventive strategies for cancer‑associated thrombosis and experimental therapies for solid tumors, with a focus on improving survival in advanced disease.

• LMWH prophylaxis in stage IV colorectal adenocarcinoma
• Investigational agents for metastatic colorectal cancer
• Combination immunotherapy trials for solid tumors

Multicenter cooperation enhances enrollment across diverse tumor types.

Research targets metabolic liver injury, testing compounds that may resolve steatohepatitis and improve systemic metabolic parameters.

• Resmetirom for NASH resolution and fibrosis improvement
• MGL‑3196 (resmetirom) effects on metabolic dysfunction‑associated steatotic liver disease
• Lanifibranor safety assessment in primary sclerosing cholangitis

Endocrinology input ensures comprehensive metabolic profiling of participants.

Clinical investigations address severe pulmonary conditions, evaluating interventions that could lower mortality and ventilator dependence in ARDS and acute hypoxemic respiratory failure.

• Aprotinin efficacy in acute respiratory distress syndrome
• Dexamethasone dosing strategies for acute hypoxemic respiratory failure
• Safety of high‑flow oxygen and non‑invasive ventilation approaches

Critical care specialists coordinate intensive monitoring and outcome assessment.

Dermatology trials explore innovative therapies for chronic skin disorders, aiming to achieve better clearance and symptom relief in conditions such as psoriasis, atopic dermatitis, and hidradenitis suppurativa.

• Adjusted brodalumab dosing for high‑weight moderate‑to‑severe psoriasis
• Long‑term safety of povorcitinib in atopic dermatitis
• Ritlecitinib efficacy in hidradenitis suppurativa

The department’s expertise in skin immunology supports precise endpoint evaluation.

Viral hepatitis studies assess novel antiviral agents and immunotherapeutic strategies to achieve functional cure and reduce liver injury in chronic hepatitis B.

• Bepirovirsen for nucleos(t)ide analogue‑treated chronic hepatitis B
• Sequential antisense oligonucleotide and immunotherapy for HBV
• GSK3228836 safety and efficacy in chronic hepatitis B

Hepatology and virology teams collaborate on viral load monitoring and serologic outcomes.

Projects investigate metabolic and physiological processes influencing gut health, including the impact of therapies on bile acid metabolism and intestinal inflammation.

• Elafibranor effects on cholestasis in primary sclerosing cholangitis
• Metabolism modulation in Crohn’s disease using targeted agents
• Oral povorcitinib evaluation for hidradenitis suppurativa with gastrointestinal comorbidities

Gastroenterology partners provide endoscopic expertise and biomarker analysis.

Studies focus on systemic metabolic pathways, testing agents that modify lipid profiles, glucose handling, and energy balance, particularly in patients with elevated lipoprotein(a) and metabolic liver disease.

• Muvalaplin impact on lipoprotein(a) and cardiovascular risk
• Semaglutide effects on liver histology in NASH
• Elafibranor dosing strategies for metabolic dysfunction‑associated steatotic liver disease

Metabolic specialists ensure comprehensive assessment of biochemical and imaging endpoints.